BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Key Highlights
- ➤BriaCell and BriaPro selected four preclinical posters for SITC 2026 presentations
- ➤BriaCell poster covers Bria-OTS+ genetically engineered whole-cell vaccine platform
- ➤BriaPro posters cover BP-80, tumor-targeted checkpoint inhibitors, and CD80 variants
- ➤SITC 2026 Annual Meeting scheduled November 4-8 in Phoenix, Arizona
Expert Statements
William V. Williams, President & CEO of BriaCell Therapeutics Corp.
“BriaCell Therapeutics Corp.”
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41(th) Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.
The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.
Get started
Create a free account to read the full story.